NCT06043700 · ACTIVE NOT RECRUITING
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
This is a screening study, not a treatment trial. Researchers are using blood tests to find people who may have high levels of amyloid protein in the brain — a biological marker associated with Alzheimer's risk — before significant symptoms appear. There is no drug or intervention involved. The goal is to build a pool of identified at-risk individuals who could then be referred to clinical trial sites. Details beyond that are limited.
Eligibility criteria
Inclusion Criteria: 1. Male or female, age 50 to 80 years inclusive, at the time of informed consent - Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection: * First degree relative with dementia onset before age 75, * Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or * Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing 2. Provide written informed consent 3. Willing and able to comply with all aspects of the protocol 4. Willing to be referred to a clinical site if the assessment results meet the criteria Exclusion Criteria: 1. Known uncontrolled medical conditions (example, cardiac, respiratory, gastrointestinal, psychiatric, renal disease, malignant neoplasm) 2. Participation in an interventional clinical trial study at the time of consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-05